Comparing Eliem Therapeutics (NASDAQ:ELYM) & CannaPharmaRX (OTCMKTS:CPMD)

Eliem Therapeutics (NASDAQ:ELYM) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Institutional & Insider Ownership

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 1.3% of CannaPharmaRX shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Eliem Therapeutics and CannaPharmaRX”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12 million	($0.53)	-12.38
CannaPharmaRX	N/A	N/A	$3.69 million	($0.01)	-1.00

Eliem Therapeutics is trading at a lower price-to-earnings ratio than CannaPharmaRX, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Eliem Therapeutics and CannaPharmaRX, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0	0	0	0	N/A
CannaPharmaRX	0	0	0	0	N/A

Profitability

This table compares Eliem Therapeutics and CannaPharmaRX’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
CannaPharmaRX	N/A	N/A	-55.33%

Volatility & Risk

Eliem Therapeutics has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500.

Summary

CannaPharmaRX beats Eliem Therapeutics on 5 of the 8 factors compared between the two stocks.

About Eliem Therapeutics

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

About CannaPharmaRX

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.